Health Trials

About this trial

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Eligibility criteria

Qualifiers

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

Contraception use during treatment and at least 90 days after final dose.

Confirmed CD19 expression if prior anti-CD19 therapy.

Participants with CLL must require treatment according to the international workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.

Disqualifiers

Central nervous system (CNS) lymphoma.

Surgery within 14 days of study drug.

Clinically significant cardiovascular (CV) disease.

Unresolved Grade >2 AEs from prior anticancer therapy (except alopecia or fatigue).

Trial design

Treatments tested in this trial

  • Surovatamig
  • Prednisone (or equivalent)
  • Rituximab
  • Cyclophosphamide
  • Vincristine
  • Doxorubicin
  • Acalabrutinib

Treatment groups

408 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Locations

64
Australia
Research Site3084, Heidelberg Australia
Research Site3004, Melbourne Australia
Research Site6009, Nedlands Australia
China
Research Site100044, Beijing China

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov